013 - Symptom Management: Dronabinol for Neuropathic Pain

Questions? Comments? Send us a message!

I. Introduction

This briefing document synthesizes key findings from several sources exploring the potential of cannabinoids in managing neuropathic pain. The sources include pre-clinical investigations, clinical trial reviews, and decision analysis models, offering a multifaceted view of the topic. We will examine the potential of Cannabidiolic Acid Methyl Ester (CBDA-ME), the effectiveness of cannabis-based medicines, and compare these to traditional pain management techniques.

II. Pre-Clinical Investigation: CBDA-ME

• Focus: The research primarily centers around CBDA-ME, a modified version of cannabidiolic acid (CBDA), which has been enhanced for stability. The study investigates its analgesic effects in rats with peripherally induced neuropathic pain, considering sex as a biological variable.
• Key Findings:
• Improved Stability: CBDA is unstable which limits its potential as a therapeutic target. The addition of the methyl ester group enhances its stability in in vivo studies.
• Dose-Dependent Analgesic Effects (Males): CBDA-ME exhibited a clear dose-dependent increase in mechanical pain threshold in male rats, with a significant reduction in sensitivity to touch. The most effective dose was 1 μg/kg. For example, at week 5, the 1 μg/kg group showed a mechanical threshold of 12.27g compared to a 4.70g for the vehicle group. By week 8, the same groups had thresholds of 12.56g vs 3.53g respectively.
• Inconsistent Results (Females): Female rats showed less consistent responses to CBDA-ME, with some increase in mechanical threshold at weeks 3-5 at 1 μg/kg, but less pronounced and less sustained than in males. At week 5 females had a threshold of 8.81g in the high dose group compared to 4.33g in the vehicle group. At week 8 the numbers were 6.20g vs 5.26g.
• Impact on Thermal Thresholds: The study found less clear or consistent effects of CBDA-ME on thermal thresholds.
• Reduced Neuronal Excitability: CBDA-ME reduced the excitability of specific sensory neuron types (AβHTM, CUT, CHTM, CLTM) by decreasing the current threshold required to evoke an action potential, suggesting a mechanism for its analgesic effect.
• Quote: "This study examines early treatment efficacy of CBDA-ME in a rat model of peripherally induced NEP and evaluates sex as a biological variable."
• Implications: These findings suggest CBDA-ME as a potential analgesic, particularly for mechanical pain, with significant sex differences that need further investigation.

III. Clinical Trial Review: Cannabis-Based Medicines (CBMs)

• Source Focus: A Cochrane review examining the effectiveness of CBMs for chronic neuropathic pain in adults.
• Key Findings:
• Herbal Cannabis: The review found that herbal cannabis was not significantly different from placebo in reducing pain or causing dropouts due to side effects, rated as very low-quality evidence.
• Short-Term Studies: CBMs were not superior to placebo in short-term studies for pain reduction or patient-reported global improvement.
• Intermediate-Term Studies: Some studies showed slight superiority of CBMs over placebo in intermediate-term studies, but these were marginal and sometimes lacked statistical significance, such as a positive Risk Difference in studies reporting improvement in pain (RD=0.03 95% CI 0.00 to 0.06, p=0.05), and similar results reported for a composite measure of improved function

Support the show

Thank you for your interest in Ethics in Palliative Medicine! Follow us at https://epionepalliative.com and on X: @PallCareEthics